Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04039607 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04039607 · ClinicalTrials.gov record · last posted 2026-08-25

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

Study acronym: CheckMate 9DW
StatusCompleted
PhasePhase 3
Started2019-09-30
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Protocol amendment history 3 changes detected by DataLookout

2026-08-26
Trial completed
2026-04-07
Primary completion moved earlier: 2026-11-09 → 2026-07-09
2026-04-07
Completion moved earlier: 2026-11-09 → 2026-07-09
Trial Details
NCT Number NCT04039607
Lead Sponsor Bristol-Myers Squibb
Conditions Hepatocellular Carcinoma
Enrollment 732 participants
Start Date 2019-09-30
Primary Completion 2026-07-09 (estimated)
Study Completion 2026-07-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-25